Zobrazeno 1 - 3
of 3
pro vyhledávání: '"The Nemolizumab-JP01 Study Group"'
Autor:
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima, The Nemolizumab-JP01 Study Group
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 997-1011 (2023)
Abstract Introduction Atopic dermatitis (AD), with its signs and symptoms of pruritus, dryness, and erythema, severely reduces the quality of life (QOL) of affected patients. We investigated the impact of nemolizumab 60 mg on QOL in Japanese patients
Externí odkaz:
https://doaj.org/article/0a6531ebcb694a83911713b2c78fabe9
Autor:
Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima, for the Nemolizumab-JP01 Study Group
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies. Method
Externí odkaz:
https://doaj.org/article/c232787a0d07422590d97f91f65ed256
Autor:
Kabashima, Kenji1 (AUTHOR), Matsumura, Takayo1 (AUTHOR), Komazaki, Hiroshi1 (AUTHOR), Kawashima, Makoto1 (AUTHOR), Nemolizumab-JP01 Study Group (CORPORATE AUTHOR)
Publikováno v:
New England Journal of Medicine. 7/9/2020, Vol. 383 Issue 2, p141-150. 10p.